The renin-angiotensin-aldosterone system inhibitors in COVID-19: from acidosis to ventilation and immunity
Main Authors: | Wan-Hui Liao, Gee-Gwo Yang, Maciej Henneberg |
---|---|
Format: | Article |
Language: | English |
Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2020-12-01
|
Series: | Swiss Medical Weekly |
Subjects: | |
Online Access: | https://www.smw.ch/index.php/smw/article/view/2914 |
Similar Items
-
Management of renin-angiotensin-aldosterone inhibitors and other antihypertensives and their clinical effects on pre-anesthesia blood pressure
by: Eda Balcı, et al.
Published: (2022-01-01) -
Chronic Metabolic Acidosis Elicits Hypertension via Upregulation of Intrarenal Angiotensin II and Induction of Oxidative Stress
by: Dinesh Aryal, et al.
Published: (2020-12-01) -
Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study)
by: Bjune T, et al.
Published: (2023-03-01) -
Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review
by: Filipe Ferrari, et al.
Published: (2021-04-01) -
Renin-angiotensin-aldosterone system inhibitors – a realm of confusion in COVID-19
by: Angela Madalina Lazar
Published: (2021-07-01)